Kavanaugh Arthur, Cassell Sarah
Division of Rheumatology, Allergy, and Immunology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0943, USA.
Curr Rheumatol Rep. 2005 Jun;7(3):195-200. doi: 10.1007/s11926-996-0039-x.
Psoriatic arthritis (PsA) is an important condition that significantly impacts affected patients. The introduction of novel therapeutic agents for PsA has generated great interest in clinical trials as well as in clinical care. Therefore, there is a great need for standardized outcome measures that can accurately assess the activity of disease and response to therapy. Because it is a heterogeneous and multifaceted condition, defining outcome measures has been a challenge. To date, such measures have largely been adapted from other similar diseases. With further research, the most appropriate outcome measures specific for PsA will be delineated.
银屑病关节炎(PsA)是一种对受影响患者有重大影响的重要病症。新型PsA治疗药物的推出在临床试验以及临床护理中引起了极大关注。因此,迫切需要能够准确评估疾病活动度和治疗反应的标准化结局指标。由于它是一种异质性和多方面的病症,定义结局指标一直是一项挑战。迄今为止,此类指标很大程度上是从其他类似疾病中改编而来的。随着进一步研究,将确定最适合PsA的结局指标。